BRAF mutation (any)

Any BRAF mutation (V600 and non-V600 classes) detected by sequencing; used as a predictive and, in some settings, prognostic marker.

CI-BIO-00000019BRAF graph →NCIt C40430 Tumor-agnostic · 4 approval rows

Also calledBRAF-mutant · BRAF-mutated · non-V600 BRAF · class II/III BRAF

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (32)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Melanoma	75	72	2	1	3 / 40 / 14 / 18 / 0
Malignant Colorectal Neoplasm	67	54	13	—	1 / 43 / 10 / 12 / 1
Cutaneous Melanoma	22	22	—	—

Derived

Drugs with predictive evidence (43)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	92	72	20	A	55 / 22	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +16
TrametinibSmall Molecule	53	51	2	A	50 / 2	Childhood Low Grade Glioma, Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma +13
DabrafenibSmall Molecule	40	33	7	A	34 / 11	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Ganglioglioma +9
CetuximabMonoclonal Antibody	24	11	13	A	9 / 10	Malignant Colorectal Neoplasm, Solid Neoplasm
PanitumumabMonoclonal Antibody	14	8	6	B	5 / 4	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	12	5	7	B	5 / 6	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	10	9	1	C	9 / 1	Childhood Pilocytic Astrocytoma, Cutaneous Melanoma, Malignant Colorectal Neoplasm, Melanoma +1
CobimetinibSmall Molecule	7	7	—	A	8 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	6	6	—	A	6 / 0	Malignant Colorectal Neoplasm, Melanoma
Mitogen-Activated Protein Kinase Kinase Inhibitor	6	6	—	B	5 / 0	Cutaneous Melanoma, Melanoma
BevacizumabMonoclonal Antibody	5	3	2	B	3 / 2	Malignant Colorectal Neoplasm, Spindle Cell Sarcoma
BRAF Inhibitor	5	5	—	B	4 / 0	Melanoma
SelumetinibSmall Molecule	5	4	1	B	2 / 2	Childhood Pilocytic Astrocytoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
OxaliplatinSmall Molecule	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm, Melanoma
TovorafenibSmall Molecule	2	2	—	A	4 / 0	Childhood Low Grade Glioma
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
TemsirolimusSmall Molecule	2	2	—	C	2 / 0	Spindle Cell Sarcoma
U0126	2	—	2	D	0 / 2	Cutaneous Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
Regorafenib AnhydrousSmall Molecule	2	1	1	C	0 / 1	Gastrointestinal Stromal Tumor
MEK Inhibitor RO4987655	2	—	2	B	—	Melanoma
AlpelisibSmall Molecule	1	1	—	B	1 / 0	Malignant Colorectal Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	A	1 / 0	Melanoma
BelvarafenibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Chemotherapy	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
Dabrafenib/Trametinib Regimen	1	1	—	C	1 / 0	Histiocytic Sarcoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
EverolimusSmall Molecule	1	1	—	D	1 / 0	Childhood Low Grade Glioma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
MEK Inhibitor REC-4881	1	1	—	C	1 / 0	Cutaneous Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
Pan-RAF Inhibitor LY3009120Small Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
RefametinibSmall Molecule	1	—	1	C	0 / 1	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (214)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 201–214 of 214 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E8
Vemurafenib	Ovarian Serous AdenocarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID3787 A stage 4B, low-grade papillary serous ovarian adenocarcinoma patient, harboring a BRAF V600E mutation was associated with response to vemurafenib monotherapy. The patient was treated with standard ch… (full text at CIViC) PMID 26490654 · Combe et al., 2015 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Solid NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	4	accepted	EID12161 In this trial, patients with advanced rare tumours harbouring BRAF V600E mutations were treated with a combination of dabrafenib and trametinib. The study included eight distinct cohorts: anaplastic t… (full text at CIViC) PMID 37059834 · Subbiah et al., 2023 · Open in CIViC	civic
〃	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID6975 Interim analysis of a basket trial evaluating the combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in previously treated V600E-mutated patients showed 11/16 patients with anap… (full text at CIViC) PMID 29072975 · Subbiah et al., 2018 · Open in CIViC	civic
Vemurafenib	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID6045 In a phase 2 “basket” study of vemurafenib in BRAF V600-positive non-melanoma cancers, seven patients with anaplastic thyroid cancer were enrolled. All 7 patients had V600E mutations. One complete res… (full text at CIViC) PMID 26287849 · Hyman et al., 2015 · Open in CIViC	civic
Pertuzumab + VemurafenibCombination	Thyroid Gland Anaplastic CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID5961 The phase 2a MyPathway study assigned patients with HER2, EGFR, BRAF or SHH alterations to treatment with pertuzumab plus trastuzumab, erlotinib, vemurafenib, or vismodegib, respectively. One patient … (full text at CIViC) PMID 29320312 · Hainsworth et al., 2018 · Open in CIViC	civic
Vemurafenib	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	3	accepted	EID1591 Open-label non-randomised phase 2 trial in patients with recurrent or metastatic BRAF V600E mutant papillary thyroid cancer refractory to radioactive iodine. Patients had (cohort 2) or had not (cohort… (full text at CIViC) PMID 27460442 · Brose et al., 2016 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	B	Supports Sensitivity Response	4	accepted	EID9018 Open label phase 2 (Clinical Level B) trial including patients from across the globe (USA, Italy, and the Netherlands) investigating sensitivity to Vemurafenib in patients that have BRAF V600E-positiv… (full text at CIViC) PMID 27460442 · Brose et al., 2016 · Open in CIViC	civic
〃	Thyroid Gland Papillary CarcinomaALIAS	Predictive	C	Supports Sensitivity Response	4	accepted	EID1414 A 73 year old patient with prior history of breast cancer presented with metastatic papillary thyroid carcinoma. After two treatments of I-131 a comprehensive tumor profile revealed BRAF V600E as the … (full text at CIViC) PMID 24987354 · Ali et al., 2014 · Open in CIViC	civic
BRAF L525R1
Cetuximab	Solid NeoplasmCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID7560 When transferred into EGFR expressing HEK293 cells, BRAF L525R induced increased ERK phosphorylation to a level similar to that induced by BRAF V600E. ERK phosphorylation enhanced by BRAF L525R was no… (full text at CIViC) PMID 28972961 · Shinozaki et al., 2017 · Open in CIViC	civic
BRAF Non-V6001
Trametinib	Solid NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID7855 In a phase II basket trial (NCI-MATCH), patients with solid tumors or hematologic malignancies harboring BRAF non-V600 mutations were treated with trametinib. Among 50 patients assigned, 32 were eligi… (full text at CIViC) PMID 31924734 · Johnson et al., 2020 · Open in CIViC	civic
BRAF G466V1
Vemurafenib	Solid NeoplasmCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID7554 RAF inhibitor vemurafenib failed to inhibit ERK signaling in tumor cells and NIH3T3 that express class 3 BRAF mutations (G466V, G466E, D594G, D594N, and G596R). PMID 28783719 · Yao et al., 2017 · Open in CIViC	civic
BRAF Fusion2
Bevacizumab + Sorafenib + TemsirolimusCombination	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID1664 A patient with a malignant spindle cell tumor of the chest wall treated as a soft tissue sarcoma was identified to harbor a KIAA1549-BRAF fusion. This patient responded to treatment with the pan-kinas… (full text at CIViC) PMID 24422672 · Subbiah et al., 2014 · Open in CIViC	civic
〃	Spindle Cell Sarcoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID7312 A patients with malignant spindle cell tumor treated as as soft tissue sarcoma harboring KIAA1549-BRAF fusion were treated with sorafenib in combination with bevacizumab and temsirolimus. Tumor of th… (full text at CIViC) PMID 26314551 · Ross et al., 2016 · Open in CIViC	civic
BRAF Fusion1
Trametinib	Transitional Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7763 In a case report, a patient with metastatic urothelial carcinoma harboring an NRF1-BRAF fusion was treated with trametinib. After two and a half months of treatment, MRI revealed 48.4% decrease in siz… (full text at CIViC) PMID 31010895 · Isaacson et al., 2019 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (458)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Alpelisib	CA Health Canada	—	Marketed in Canada as PIQRAY (DIN 02497077) under ATC L01EM03 ALPELISIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 29, 2020	health-canada-dpd
Alpelisib	CA Health Canada	—	Marketed in Canada as PIQRAY (DIN 02497085) under ATC L01EM03 ALPELISIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jun 29, 2020	health-canada-dpd
Alpelisib	CA Health Canada	—	Marketed in Canada as PIQRAY (DIN 02497069) under ATC L01EM03 ALPELISIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (629)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 333 recruiting · 118 active phase 3 · 2,987 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 601–629 of 629 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03767075	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets)(BoB)	recruiting	Phase 2	1,000	Vall d'Hebron Institute of OncologyOTHER	7	Apr 25, 2024	clinicaltrials
NCT06373133	SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer	not yet recruiting	Phase 1 / Phase 2	36	West China HospitalOTHER	0	Apr 18, 2024	clinicaltrials
NCT06259058	Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer	not yet recruiting	Phase 1 / Phase 2	96	Tianjin Medical University Cancer Institute and HospitalOTHER	0	Mar 15, 2024	clinicaltrials
NCT06307249	Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA)	recruiting	Phase 1	50	Lebanese UniversityOTHER	1	Mar 12, 2024	clinicaltrials
NCT05007132	Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer	recruiting	Phase 2	153	Dominik Paul ModestOTHER	1	Feb 15, 2024	clinicaltrials
NCT03494946	Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer(SECAIII)	recruiting	N/A	30	Oslo University HospitalOTHER	1	Feb 6, 2024	clinicaltrials
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)(DRUP)	recruiting	Phase 2	1,550	The Netherlands Cancer InstituteOTHER	1	Jan 24, 2024	clinicaltrials
NCT06192680	Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer	not yet recruiting	Phase 2	63	Harbin Medical UniversityOTHER	0	Jan 18, 2024	clinicaltrials
NCT06210360	Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX	not yet recruiting	Phase 2	134	Changhai HospitalOTHER	0	Jan 18, 2024	clinicaltrials
NCT06159478	Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume)(Perfume)	recruiting	Phase 2	32	National Cancer Center, JapanOTHER_GOV	1	Dec 13, 2023	clinicaltrials
NCT06121700	Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer(Miracle-G)	recruiting	Phase 2	55	Fudan UniversityOTHER	1	Nov 8, 2023	clinicaltrials
NCT06102837	Tumor Vaccines for Solid Tumors	recruiting	—	340	Huashan HospitalOTHER	1	Oct 26, 2023	clinicaltrials
NCT06079333	NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)(NEO-ATACT)	recruiting	Phase 2	20	Leiden University Medical CenterOTHER	1	Oct 12, 2023	clinicaltrials
NCT06067776	Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer	not yet recruiting	Phase 1	36	Jonathan RiessOTHER	1	Oct 5, 2023	clinicaltrials
NCT06063070	First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer	not yet recruiting	Phase 2	44	Sun Yat-sen UniversityOTHER	1	Oct 2, 2023	clinicaltrials
NCT04728724	Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer	recruiting	Phase 2	100	Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER	1	Sep 13, 2023	clinicaltrials
NCT03563729	Melanoma Metastasized to the Brain and Steroids(MEMBRAINS)	recruiting	Phase 2	80	Inge Marie SvaneOTHER	1	Jul 13, 2023	clinicaltrials
NCT05354674	Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver Metastasis	not yet recruiting	—	302	Fudan UniversityOTHER	1	Jul 13, 2023	clinicaltrials
NCT05797467	Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients	recruiting	Phase 3	366	Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER	1	May 24, 2023	clinicaltrials
NCT05797077	Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA	recruiting	Phase 3	346	Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER	1	Apr 4, 2023	clinicaltrials
NCT05725200	Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer(EVIDENT)	recruiting	Phase 2	40	Oslo University HospitalOTHER	1	Feb 21, 2023	clinicaltrials
NCT04304209	Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer	active not recruiting	Phase 2	195	Sun Yat-sen UniversityOTHER	1	Feb 1, 2023	clinicaltrials
NCT05699746	CAPEOX vs Observation in Colorectal Cancer Patients With Positive MRD	not yet recruiting	Phase 3	38	Zhejiang UniversityOTHER	1	Jan 26, 2023	clinicaltrials
NCT05607329	Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Relapsed Ovarian Cancer After PARPi Maintenance Treatment: a Multicentre, Open-label, Randomised, Phase 3 Trial	recruiting	N/A	400	Women's Hospital School Of Medicine Zhejiang UniversityOTHER	1	Nov 7, 2022	clinicaltrials
NCT05429515	Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury	not yet recruiting	Phase 4	50	Peking Union Medical College HospitalOTHER	0	Jun 23, 2022	clinicaltrials
NCT05186506	A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer	not yet recruiting	Phase 2	152	Sichuan UniversityOTHER	0	Jan 11, 2022	clinicaltrials
NCT01638676	A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients	recruiting	Phase 1 / Phase 2	55	University of LouisvilleOTHER	1	Oct 29, 2021	clinicaltrials
NCT04045691	Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment(BERING)	recruiting	—	750	Pierre Fabre Pharma GmbHINDUSTRY	3	Jan 19, 2021	clinicaltrials
NCT02446431	Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence(Metronomic)	recruiting	Early Phase 1	20	Miller Children's & Women's Hospital Long BeachOTHER	1	May 18, 2015	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (32)

Drugs with predictive evidence (43)

Predictive evidence items (214)

Approvals mentioning the linked drugs (458)

Active trials (629)

Linked publications (142)